Profile: AbbVie Inc (ABBV.N)
20 Jul 2018
AbbVie Inc. (AbbVie), incorporated on April 10, 2012, is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions. It offers products in various categories, including HUMIRA (adalimumab), Oncology products, Virology Products, Additional Virology products, Metabolics/Hormones products, Endocrinology products and other products.
HUMIRA is a biologic therapy administered as a subcutaneous injection. It is approved to treat the autoimmune diseases, such as Rheumatoid arthritis (moderate to severe), Psoriatic arthritis, Ankylosing spondylitis, Adult Crohn's disease (moderate to severe), Plaque psoriasis (moderate to severe chronic), Ulcerative colitis (moderate to severe), Pediatric Crohn's disease (moderate to severe), Hidradenitis Suppurativa (moderate to severe), non-infectious intermediate, posterior and panuveitis, and Juvenile idiopathic arthritis (moderate to severe polyarticular) in North America and the European Union. It is also approved to treat the autoimmune diseases, such as Axial spondyloarthropathy and Pediatric enthesitis-related arthritis in the European Union. It is also approved in Japan for the treatment of intestinal Behcet's disease.
AbbVie's oncology products targets cancers, including hematologic and solid cancers. These products include IMBRUVICA (ibrutinib) and Venclexta (venetoclax). IMBRUVICA is an oral and once-daily therapy that inhibits a protein called Bruton's tyrosine kinase (BTK). It is approved for the treatment of patients with chronic lymphocytic leukemia (CLL). It is also approved for the treatment of patients with mantle cell lymphoma (MCL), who have received at least one prior therapy. It also treats patients with relapsed/refractory marginal zone lymphoma (MZL). Venclexta is approved to treat people with chronic lymphocytic leukemia (CLL). It is approved for the treatment that targets the B-cell lymphoma 2 (BCL-2) protein, which supports cancer cell growth.
The Company's Virology products address the needs for patients with the HCV and HIV-1. Its HCV product, VIEKIRA PAK (ombitasvir, paritaprevir and ritonavir tablets; dasabuvir tablets), which is an all-oral, short-course, interferon-free therapy, with or without ribavirin, for the treatment of adult patients with genotype 1 chronic HCV, including those with compensated cirrhosis. In Europe, its HCV treatment is marketed as VIEKIRAX + EXVIERA and is approved for use in patients with genotype 1 and genotype 4 HCV. AbbVie's TECHNIVIE (ombitasvir, paritaprevir and ritonavir) is also approved for use in combination with ribavirin for the treatment of adults with genotype 4 HCV infection in the United States.
The Company's additional virology products include Kaletra (lopinavir/ritonavir), Norvir (ritonavir) and Synagis (palivizumab). Kaletra is a prescription anti-HIV-1 medicine that contains two protease inhibitors: lopinavir and ritonavir. It is used with other anti-HIV-1 medications as a treatment that maintains viral suppression in people with HIV-1. Norvir is a protease inhibitor that is indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection. Synagis is a product marketed by AbbVie outside of the United States that protects at-risk infants from severe respiratory disease caused by respiratory syncytial virus (RSV).
The Company's metabolic and hormone products target various conditions, including testosterone deficiency due to certain underlying conditions, exocrine pancreatic insufficiency and hypothyroidism. These products include AndroGel (testosterone gel), Creon (pancrelipase) and Synthroid (levothyroxine sodium tablets). AndroGel is a testosterone replacement therapy for males diagnosed with symptomatic low testosterone due to certain underlying conditions. Creon is a pancreatic enzyme therapy for exocrine pancreatic insufficiency, a condition that occurs in patients with cystic fibrosis, chronic pancreatitis and several other conditions. Synthroid is used in the treatment of hypothyroidism. It has the rights to sell these products only in the United States.
AbbVie's endocrinology product, Lupron (leuprolide acetate), which is also marketed as Lucrin and Lupron Depot, is a product for the palliative treatment of advanced prostate cancer, treatment of endometriosis and central precocious puberty and for the preoperative treatment of patients with anemia caused by uterine fibroids. Lupron is approved for daily subcutaneous injection and one-month, three-month, four-month and six-month intramuscular injection.
The Company's other products include Duopa and Duodopa (carbidopa and levodopa), Anesthesia products and ZINBRYTA (daclizumab). Its levodopa-carbidopa intestinal gel for the treatment of advanced Parkinson's disease is marketed as Duopa in the United States and as Duodopa outside of the United States. Sevoflurane, which is sold under the trademarks Ultane and Sevorane, is an anesthesia product that it sells around the world for human use. ZINBRYTA is a once-monthly, self-administered, subcutaneous treatment for relapsing forms of multiple sclerosis (MS).
1 N Waukegan Rd
NORTH CHICAGO IL 60064-1802
Company Web Links
- Mylan signs U.S. license deal on Humira with AbbVie
- Mylan signs U.S. license deal on Humira with AbbVie
- AbbVie wins reversal of $140 million verdict in case over AndroGel risks
- UPDATE 2-AbbVie wins reversal of $140 mln verdict in case over AndroGel risks
- U.S. judge tosses $140 mln verdict against AbbVie in AndroGel case